BR9814736A - Sal de bissulfato, e, forma de dosagem farmacêutica - Google Patents

Sal de bissulfato, e, forma de dosagem farmacêutica

Info

Publication number
BR9814736A
BR9814736A BR9814736-6A BR9814736A BR9814736A BR 9814736 A BR9814736 A BR 9814736A BR 9814736 A BR9814736 A BR 9814736A BR 9814736 A BR9814736 A BR 9814736A
Authority
BR
Brazil
Prior art keywords
bisulfate salt
dosage form
pharmaceutical dosage
salt
bisulfate
Prior art date
Application number
BR9814736-6A
Other languages
English (en)
Inventor
Janak Singh
Madhusudhan Pudipeddi
Mark D Lindrud
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22104737&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9814736(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR9814736A publication Critical patent/BR9814736A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"SAL DE BISSULFATO, E, FORMA DE DOSAGEM FARMACêUTICA" A presente invenção provê o sal de bissulfato cristalino da fórmula que observou-se ter inesperadamente alto índice de solubilidade/dissolução e biodisponibilidade oral em relação à forma de base livre deste composto inibidor da protease do HIV de azapeptídeo.
BR9814736-6A 1998-01-20 1998-12-22 Sal de bissulfato, e, forma de dosagem farmacêutica BR9814736A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7196898P 1998-01-20 1998-01-20
PCT/US1998/027382 WO1999036404A1 (en) 1998-01-20 1998-12-22 Bisulfate salt of hiv protease inhibitor

Publications (1)

Publication Number Publication Date
BR9814736A true BR9814736A (pt) 2000-10-24

Family

ID=22104737

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9814736-6A BR9814736A (pt) 1998-01-20 1998-12-22 Sal de bissulfato, e, forma de dosagem farmacêutica

Country Status (39)

Country Link
US (1) US6087383A (pt)
EP (1) EP1056722B1 (pt)
JP (2) JP4860037B2 (pt)
KR (1) KR100559283B1 (pt)
CN (1) CN1116282C (pt)
AR (1) AR014417A1 (pt)
AT (1) ATE219057T1 (pt)
AU (1) AU735875B2 (pt)
BG (1) BG64774B1 (pt)
BR (1) BR9814736A (pt)
CA (1) CA2317736C (pt)
CO (1) CO4970820A1 (pt)
CZ (1) CZ293507B6 (pt)
DE (1) DE69806067T2 (pt)
DK (1) DK1056722T3 (pt)
EE (1) EE04434B1 (pt)
EG (1) EG23936A (pt)
ES (1) ES2178300T3 (pt)
GE (1) GEP20033026B (pt)
HK (2) HK1033667A1 (pt)
HU (1) HU227196B1 (pt)
IL (2) IL137384A0 (pt)
LT (1) LT4780B (pt)
LV (1) LV12522B (pt)
MY (1) MY114838A (pt)
NO (1) NO315605B1 (pt)
NZ (1) NZ504417A (pt)
PE (1) PE20000185A1 (pt)
PL (1) PL190744B1 (pt)
PT (1) PT1056722E (pt)
RO (1) RO118869B1 (pt)
RU (1) RU2186070C2 (pt)
SK (1) SK283975B6 (pt)
TR (1) TR200001876T2 (pt)
TW (1) TW531531B (pt)
UA (1) UA59432C2 (pt)
UY (1) UY25345A1 (pt)
WO (1) WO1999036404A1 (pt)
ZA (1) ZA9956B (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2448084A1 (en) * 2001-05-22 2002-11-28 Elan Pharmaceuticals, Inc. Aza hydroxylated ethyl amine compounds
US7193065B2 (en) * 2001-07-13 2007-03-20 Roche Diagnostics Operations, Inc. Protease inhibitor conjugates and antibodies useful in immunoassay
US7157561B2 (en) * 2001-07-13 2007-01-02 Roche Diagnostics Operations, Inc. Methods of inhibiting transmission of a costimulatory signal of lymphocytes
AU2004206827A1 (en) * 2003-01-14 2004-08-05 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
TW200534879A (en) * 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
US20050256314A1 (en) * 2004-05-04 2005-11-17 Soojin Kim Process employing controlled crystallization in forming crystals of a pharmaceutical
CN1980666B (zh) * 2004-05-04 2011-03-30 布里斯托尔-迈尔斯斯奎布公司 制备阿扎那韦硫酸氢盐的方法和新的形式
US7829720B2 (en) * 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
US20050288343A1 (en) * 2004-05-19 2005-12-29 Andrew Rusowicz Process of preparing substituted carbamates and intermediates thereof
TWI354569B (en) * 2004-05-28 2011-12-21 Bristol Myers Squibb Co Coated tablet formulation and method
US7642049B2 (en) 2006-06-30 2010-01-05 Bristol-Myers Squibb Company Method for identifying HIV-1 protease inhibitors with reduced metabolic affects through detection of human resistin polymorphisms
WO2008011117A2 (en) * 2006-07-21 2008-01-24 Gilead Sciences, Inc. Antiviral protease inhibitors
BG66056B1 (bg) * 2006-10-05 2010-12-30 Красимир ДЕЧЕВ Метод и инсталация за производство на трисезонна добавка към дизелово гориво
US20090036357A1 (en) * 2007-06-12 2009-02-05 Concert Pharmaceuticals, Inc. Azapeptide derivatives
DE602008005462D1 (de) * 2007-06-22 2011-04-21 Bristol Myers Squibb Co Tablettierte atazanavirhaltige zusammensetzungen
AU2008268627A1 (en) * 2007-06-22 2008-12-31 Bristol-Myers Squibb Company Tableted compositions containing atazanavir
PL2178513T3 (pl) * 2007-06-22 2011-09-30 Bristol Myers Squibb Holdings Ireland Kompozycje w tabletkach zawierające atazanawir
KR101686243B1 (ko) * 2007-06-22 2016-12-13 브리스톨-마이어스 스퀴브 홀딩스 아일랜드 아타자나비르를 함유하는 정제 조성물
AP2490A (en) * 2007-06-29 2012-10-04 Gilead Sciences Inc Therapeutic compositions and the use thereof
BRPI0813000A2 (pt) * 2007-06-29 2014-12-23 Gilead Sciences Inc Composições terapêuticas e uso das mesmas
WO2009136365A1 (en) * 2008-05-08 2009-11-12 Ranbaxy Laboratories Limited Process for the preparation of 3,4-epoxy-2-amino-1-substituted butane derivatives and intermediate compounds thereof
WO2010070611A1 (en) 2008-12-18 2010-06-24 Ranbaxy Laboratories Limited Atazanavir formulations
US8552036B2 (en) 2009-01-12 2013-10-08 Hetero Research Foundation Polymorph of atazanavir sulfate
EP2435037B1 (en) 2009-05-27 2014-11-12 Merck Sharp & Dohme Corp. Hiv protease inhibitors
EP2272830A1 (en) 2009-06-18 2011-01-12 Esteve Química, S.A. Preparation process of an antivirally heterocyclic azahexane derivative
WO2011027324A1 (en) 2009-09-03 2011-03-10 Ranbaxy Laboratories Limited Polymorphic forms of atazanavir sulfate
EP2493312B1 (en) 2009-10-26 2021-10-20 Merck Sharp & Dohme Corp. Solid pharmaceutical compositions containing an integrase inhibitor
WO2011080562A1 (en) 2009-12-29 2011-07-07 Hetero Research Foundation Novel aza-peptides containing 2,2-disubstituted cyclobutyl and/or substituted alkoxy benzyl derivatives as antivirals
AU2011209788C1 (en) 2010-01-27 2014-08-28 Viiv Healthcare Company Antiviral therapy
WO2011107843A2 (en) 2010-03-01 2011-09-09 Lupin Limited Process for the preparation of atazanavir sulfate substantially free of diastereomers
CN102917695A (zh) 2010-04-09 2013-02-06 百时美施贵宝公司 具有改进的pH效应的阿扎那韦硫酸盐制剂
CA2849546A1 (en) 2010-09-28 2012-04-05 Ratiopharm Gmbh Dry processing of atazanavir
WO2013014633A1 (en) 2011-07-27 2013-01-31 Ranbaxy Laboratories Limited Process for preparation of atazanavir or its bisulfate salt
US8461347B2 (en) 2011-08-05 2013-06-11 Scinopharm Taiwan, Ltd. Process for preparing form A of atazanavir sulfate
EP2771332B1 (en) 2011-10-26 2016-06-29 Merck Canada Inc. Thiophen and thiazol sulfonamid derivatives as HIV protease inhibitors for the treatment of AIDS
EP2888230A4 (en) 2012-08-24 2017-07-19 Laurus Labs Private Limited Improved process for the preparation of atazanavir bisulfate
WO2014036690A1 (zh) * 2012-09-04 2014-03-13 上海迪赛诺化学制药有限公司 制备阿扎那韦硫酸氢盐a型结晶的方法
EP2956439B1 (en) 2013-02-12 2019-01-09 Cipla Limited Process for preparing atazanavir sulphate
CN104250224A (zh) * 2013-06-28 2014-12-31 上海威智医药科技有限公司 阿扎那韦富马酸盐及其制备和应用
CN104250225A (zh) * 2013-06-28 2014-12-31 上海威智医药科技有限公司 阿扎那韦磷酸盐及其制备和应用
CN104250223B (zh) * 2013-06-28 2017-04-12 上海威智医药科技有限公司 阿扎那韦氢溴酸盐及其制备和应用
CN105859611A (zh) * 2016-04-18 2016-08-17 上海现代制药海门有限公司 一种阿扎那韦硫酸氢盐a型结晶的制备方法
CN109251165B (zh) * 2018-10-02 2022-09-23 国药集团川抗制药有限公司 阿扎那韦达二4-氨基苯磺酸盐及其制备方法
CN111349042B (zh) * 2018-12-20 2023-07-14 陕西理工大学 一种阿扎那韦单晶及其制备方法
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW409125B (en) * 1996-04-22 2000-10-21 Novartis Ag Antivirally active heterocyclic azahexane derivatives
US5849911A (en) * 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives

Also Published As

Publication number Publication date
UA59432C2 (uk) 2003-09-15
ZA9956B (en) 2000-07-05
BG104618A (en) 2001-02-28
KR20010034221A (ko) 2001-04-25
CZ20002564A3 (cs) 2000-10-11
CO4970820A1 (es) 2000-11-07
BG64774B1 (bg) 2006-03-31
EE200000798A (et) 2002-06-17
AU2010199A (en) 1999-08-02
US6087383A (en) 2000-07-11
UY25345A1 (es) 2000-12-29
WO1999036404A1 (en) 1999-07-22
PE20000185A1 (es) 2000-05-14
DE69806067D1 (de) 2002-07-18
NZ504417A (en) 2001-09-28
JP2002509136A (ja) 2002-03-26
HUP0101389A2 (hu) 2001-08-28
HK1033667A1 (en) 2001-09-14
EP1056722A4 (en) 2001-01-10
PT1056722E (pt) 2002-09-30
JP2009102357A (ja) 2009-05-14
AU735875B2 (en) 2001-07-19
EE04434B1 (et) 2005-02-15
NO315605B1 (no) 2003-09-29
TR200001876T2 (tr) 2000-11-21
ES2178300T3 (es) 2002-12-16
ATE219057T1 (de) 2002-06-15
HUP0101389A3 (en) 2003-07-28
MY114838A (en) 2003-01-31
HK1033458A1 (en) 2001-08-31
PL190744B1 (pl) 2006-01-31
SK10622000A3 (sk) 2001-02-12
DE69806067T2 (de) 2003-01-23
LT4780B (lt) 2001-04-25
GEP20033026B (en) 2003-07-25
IL137384A0 (en) 2001-07-24
EG23936A (en) 2008-01-14
LV12522B (en) 2000-10-20
EP1056722B1 (en) 2002-06-12
CA2317736A1 (en) 1999-07-22
AR014417A1 (es) 2001-02-28
CA2317736C (en) 2004-11-02
IL137384A (en) 2006-08-01
DK1056722T3 (da) 2002-09-30
CZ293507B6 (cs) 2004-05-12
PL342019A1 (en) 2001-05-07
KR100559283B1 (ko) 2006-03-15
LV12522A (en) 2000-08-20
SK283975B6 (sk) 2004-06-08
RO118869B1 (ro) 2003-12-30
CN1283188A (zh) 2001-02-07
HU227196B1 (en) 2010-10-28
JP4860037B2 (ja) 2012-01-25
NO20003692L (no) 2000-07-19
LT2000067A (en) 2000-11-27
EP1056722A1 (en) 2000-12-06
TW531531B (en) 2003-05-11
NO20003692D0 (no) 2000-07-19
CN1116282C (zh) 2003-07-30
RU2186070C2 (ru) 2002-07-27

Similar Documents

Publication Publication Date Title
BR9814736A (pt) Sal de bissulfato, e, forma de dosagem farmacêutica
NO20045434L (no) En kombinasjon av en NMDA-antagonist og acetylkolinesteraseinhibitorer for behandlingen av Alzheimers sykdom
BR0109836A (pt) Processo de sìntese de perindopril e de seus sais farmaceuticamente aceitáveis
TWI262805B (en) Pharmaceutical composition for treating or inhibiting colonic polyps
GEP20094625B (en) Amidino compound and salts thereof useful as nitric oxide synthase inhibitors
UY26754A1 (es) Derivados de la 1, 3, 8, -triaza-spiro (4,5) decan-4-ona
NO20013220D0 (no) Trombineinhibitorer
EP1018514A4 (en) NF- $ g (k) B INHIBITORS CONTAINING INDANE DERIVATIVES AS ACTIVE INGREDIENT
BR9911160A (pt) Ciclosporinas
BR0109356A (pt) Inibidores de protease
BR0012901A (pt) Medicamentos de ß - carbolina
DK0715623T3 (da) Blodpladeaggregationsinhibitorer
UY26780A1 (es) Cicloalquil avb3 antagonistas
BR0212069A (pt) Agentes antidiabéticos orais
UY26851A1 (es) Derivados de la 4-fenilpiridina
ATE322487T1 (de) Hydroxamsäure-derivate
BR0101230A (pt) Processo para a preparação de11-amino-3-cloro-6,11-diidro-5-5-dioxo-6-metil-dibenzo[c,f][1,2]tiazepina e aplicação para a sìntese detianeptina
BR9810657A (pt) "processo de preparação de um per-hidroisoindol substituìdo"
ES2159362T3 (es) Utilizacion de la 1-(2-naft-2-iletil)-4-(3-trifluorometilfenil)-1,2,3,6-tetrahidropiridina para la preparacion de medicamentos destinados para el tratamiento de la esclerosis lateral amiotrofica.
FR2818906B1 (fr) Association medicamenteuse d'une biguanine et d'un transporteur, par exemple de metformine et d'arginine
BR9814495A (pt) Composto, processo para prepará-lo, uso do mesmo, composição farmacêutica, e, processo
ITMI911853A1 (it) Sale del diclofenac, metodo di preparazione e composizioni farmaceutiche che lo contengono.
NO941084L (no) Neuroleptiske 2-substituerte perhydro-1-H-pyrido[1,2-aÅpyraziner
HN2002000354A (es) Sales de acido citrico de un compuesto terapeutico y composiciones farmaceuticas que la contienen
ATE233106T1 (de) Stabile radioaktive medikamente

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1865 DE 03/10/2006 POR TER APRESENTADA PAPELETA DE ESCLARECIMENTO.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 8O DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.